NextCell presentation of Interim analysis data today at 15:00
NextCell Pharma AB ("NextCell" or the "Company") has developed a proprietary and patented platform technology where stem cells can be selected for allogeneic treatment of various specific diseases. CEO Mathias Svahn will present the results on Thursday, October 27 at 15:00 CET, which will be broadcast live via Nyhetsbytrån Direkt, link https://youtu.be/Y9BSbt31tqc. · Thursday, October 27, CET 3:00 pm · https://youtu.be/Y9BSbt31tqcBelow follows an update on the Company's completed and ongoing clinical trials with the drug candidate ProTrans, which has been developed for type-1